-The Business Standard State must get out of insulin price-setting The National Pharmaceutical Pricing Authority, or NPPA, has turned down the request of drug companies to raise insulin prices. Domestic insulin-makers Biocon and Cadila had argued that the cost of production and packaging had become higher, and multinational corporation Eli Lilly wanted the depreciation in the rupee vis-à-vis the dollar to be factored into the price. The NPPA says it has...

-Live Mint Natco Pharma Ltd, which has started selling a generic version of Bayer AG’s patented cancer treatment Nexavar in India at a fraction of the price charged by the German firm, plans to use the so-called compulsory licensing route to try and win the right to copy more patented drugs, said vice-chairman and chief executive officer Rajeev Nannapaneni. The Hyderabad-based company has already identified the patented drugs for which it will...

-The Times of India DANTEWADA: Six-year-old Shiva Yadav sang softly to Shahid Khan, about two-and-half-years-old, trying to lull him to sleep. Their mothers — Vime Yadav and Kureshia Begum — were busy chopping vegetables for dinner of 250 children at Dantewada's Aastha hostel in south Chhattisgarh. Vime is a cook and Kureshia works as a peon at the state government-run Aastha. They landed the jobs after their husbands were killed in...

Tuberculosis re-emerges as a major threat as new drug-resistant strains develop because of mismanagement of the disease. At the beginning of the year, doctors at Mumbai’s P.D. Hinduja National Hospital and Medical Research Centre reported that they had 12 patients infected with TDR-TB, or totally drug-resistant tuberculosis, a condition in which the TB bacilli is resistant to all first- and second-line drugs used in the conventional treatment of the disease. Panic...

-The Economic Times It's not just the drug regulator, where a parliamentary panel has alleged corruption, failing in its job. Drug regulation across entities that dot this broad landscape is in poor health and ineffective. In May, when a Parliamentary panel, during a routine examination of healthcare regulatory bodies, alleged corruption in the approval of new drugs, it was merely pointing out one symptom. Such symptoms pervade the entire drug regulation landscape,...